Therapeutic receptor-blocking concentrations of neuroleptics

被引:36
作者
Seeman, P [1 ]
机构
[1] UNIV TORONTO,DEPT PSYCHIAT,TORONTO,ON M5S 1A8,CANADA
关键词
neuroleptic; clozapine; dopamine receptor; haloperidol; seroquel; risperidone; schizophrenia; Parkinson's disease;
D O I
10.1097/00004850-199509000-00002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The therapeutic concentrations of antipsychotic drugs in the patient's plasma water or spinal fluid are identical to their blocking potencies in vitro at the dopamine D-2 receptor, with the exception of clozapine which acts at D-2. The variation in K values between laboratories stems from the fact that the apparent K value for any antipsychotic drug depends on the affinity of the competing radioligand for the receptor or the membranes. Clozapine at the D-2 receptor has a K value of 420 nM, using [H-3]nemonapride, 180 nM using [H-3]spiperone and 82 nM using [H-3]raclopride. These K values are related to the tissue/buffer partition coefficients of the ligands. Extrapolating down to either 1 or 0 partition yields the intrinsic K values for the antipsychotic in the absence of any competing ligand. The extrapolated or intrinsic K value for clozapine at D-4 is 1.3 nM, in agreement with the value of 1.1 nM measured directly with [H-3]clozapine at D-4. Clozapine in vivo, however, must compete with endogenous dopamine in the synapse, estimated as 50 nM. Thus, the in vivo concentration of clozapine for 75% occupation of dopamine D-4 receptors can be derived as similar to 14 nM, in agreement with the observed value of 12-20 nM in the plasma water or spinal fluid in treated patients. In L-DOPA psychosis in Parkinson's disease, the clozapine concentration (in the plasma water or spinal fluid) for 75% blockade of dopamine D-4 receptors mag be predicted as similar to 3 nM, in general agreement with the value of similar to 1.2 nM in Parkinson patients who have L-DOPA psychosis. These considerations provide strong support for the conclusion that clozapine primarily targets the D-4 receptor in psychosis. Using the same considerations for haloperidol, it can be shown that the haloperidol therapeutic concentration required for 75% blockade of dopamine D-2 receptors in vivo will be approximately 2-3 nM, in agreement with the observed value in the spinal fluid or plasma water of 1-3 nM.
引用
收藏
页码:5 / 13
页数:9
相关论文
共 40 条
[1]   RECEPTOR ACTIVITY AND TURNOVER OF DOPAMINE AND NORADRENALINE AFTER NEUROLEPTICS [J].
ANDEN, NE ;
BUTCHER, SG ;
CORRODI, H ;
FUXE, K ;
UNGERSTEDT, U .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1970, 11 (03) :303-+
[2]  
ASGHARI V, 1995, IN PRESS J NEUROCHEM
[3]  
CASEY DE, 1991, AM COLL NEUROPSYCHOP, V30, P127
[4]   DOPAMINE RECEPTOR-BINDING PREDICTS CLINICAL AND PHARMACOLOGICAL POTENCIES OF ANTI-SCHIZOPHRENIC DRUGS [J].
CREESE, I ;
BURT, DR ;
SNYDER, SH .
SCIENCE, 1976, 192 (4238) :481-483
[5]  
DARDE L, 1993, AM COLLEGE NEUROPSYC, V32, P38
[6]   RITANSERIN, A SELECTIVE 5-HT(2/1C) ANTAGONIST, AND NEGATIVE SYMPTOMS IN SCHIZOPHRENIA - A PLACEBO-CONTROLLED DOUBLE-BLIND TRIAL [J].
DUINKERKE, SJ ;
BOTTER, PA ;
JANSEN, AAI ;
VANDONGEN, PAM ;
VANHAAFTEN, AJ ;
BOOM, AJ ;
VANLAARHOVEN, JHM ;
BUSARD, HLSM .
BRITISH JOURNAL OF PSYCHIATRY, 1993, 163 :451-455
[7]   PET ANALYSIS INDICATES ATYPICAL CENTRAL DOPAMINE RECEPTOR OCCUPANCY IN CLOZAPINE-TREATED PATIENTS [J].
FARDE, L ;
NORDSTROM, AL .
BRITISH JOURNAL OF PSYCHIATRY, 1992, 160 :30-33
[8]   POSITRON EMISSION TOMOGRAPHY STUDIES ON D-2 AND 5-HT2 RECEPTOR-BINDING IN RISPERIDONE-TREATED SCHIZOPHRENIC-PATIENTS [J].
FARDE, L ;
NYBERG, S ;
OXENSTIERNA, G ;
NAKASHIMA, Y ;
HALLDIN, C ;
ERICSSON, B .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1995, 15 (01) :S19-S23
[9]  
FARDE L, 1992, ARCH GEN PSYCHIAT, V49, P538
[10]   SELECTIVE D1-DOPAMINE AND D2-DOPAMINE RECEPTOR BLOCKADE BOTH INDUCES AKATHISIA IN HUMANS - A PET STUDY WITH [C-11] SCH-23390 AND [C-11] RACLOPRIDE [J].
FARDE, L .
PSYCHOPHARMACOLOGY, 1992, 107 (01) :23-29